Safety and tolerability of short‐term infusions of intravenous lacosamide in pediatric patients with epilepsy: An open‐label, phase 2/3 trial
Epilepsia Open · 2023
DOI: 10.1002/epi4.12682 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Epilepsia Open, 2023. Verfasst von Mark Kristof Farkas und 7 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Pediatrics, Semmelweis University, Budapest, Hungary. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UCB Pharma.
Abstract (Originalsprache)
Objective The objective of this study is to evaluate the safety and tolerability of intravenous (IV) lacosamide infusion in patients aged ≥1 month to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Department of Pediatrics, Semmelweis University, Budapest, Hungary.
- UCB Pharma, Morrisville, North Carolina, USA.
- UCB Pharma, Monheim am Rhein, Germany.
- Dnipro City Pediatric Clinical Hospital, Dnipro, Ukraine.
ORCID-Profile: Mark Kristof Farkas
Förderung
- UCB Pharma
Zitieren
APA
Farkas, M. K., Beller, C., Bozorg, A., McClung, C., Roebling, R., Yates, T., Yuen, N., & Makedonska, I. (2023). Safety and tolerability of short‐term infusions of intravenous lacosamide in pediatric patients with epilepsy: An open‐label, phase 2/3 trial. Epilepsia Open. https://doi.org/10.1002/epi4.12682
Vancouver
Farkas MK, Beller C, Bozorg A, McClung C, Roebling R, Yates T, et al. Safety and tolerability of short‐term infusions of intravenous lacosamide in pediatric patients with epilepsy: An open‐label, phase 2/3 trial. Epilepsia Open. 2023. doi:10.1002/epi4.12682
BibTeX
@article{Farkas2023,
author = {Farkas, Mark Kristof and Beller, Cynthia and Bozorg, Ali and McClung, Carrie and Roebling, Robert and Yates, Tanisia and Yuen, Nancy and Makedonska, Iryna},
title = {Safety and tolerability of short‐term infusions of intravenous lacosamide in pediatric patients with epilepsy: An open‐label, phase 2/3 trial},
journal = {Epilepsia Open},
year = {2023},
doi = {10.1002/epi4.12682}
}
EUVIMED